SARS-CoV-2
Aiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patch
Excerpt from the Press Release: An East Bay company formulated a Covid-19 vaccine candidate to load onto a patch of 2,000 microneedles, one of several efforts globally to make it easier to take drugs and vaccines to combat the pandemic. Zosano Pharma Corp. (NASDAQ: ZSAN) of Fremont did not disclose the name of the vaccine,…
Read More
Excerpt from the Press Release: Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2. Now, new research led by investigators at Harvard Medical School and Boston Children’s Hospital points to a well-known…
Read More
Excerpt from the Press Release: We are pleased that The Lancet, a trusted source of clinical, public health and global health knowledge, published Phase 3 data showing the COVID-19 vaccine candidate, COVAXIN™ (BBV152), has 93.4% efficacy against severe COVID-19 disease. COVAXIN™ (BBV152), a whole virion inactivated COVID-19 vaccine candidate, uses the same technology that is safely and effectively applied in the production of Bharat…
Read More
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health Organization Pediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating comparable neutralizing antibody response as seen in a large adult Phase 3 clinical trial conducted in India COVAXIN™ (BBV152) uses same Vero Cell manufacturing platform as other childhood vaccines,…
Read More
Excerpt from the Press Release: Data from 10,000 individuals affected by SARS-CoV-2 will be used to identify biomarkers that can help predict potential risk of serious disease and support the development of novel therapeutics to combat COVID-19 SAN DIEGO, Nov. 3, 2021 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN) today announced that its world-class sequencing and bioinformatics solutions…
Read More
Scientists at La Jolla Institute for Immunology received $2.6 million as part of a larger effort to develop protective shots against past, present and future coronaviruses. Excerpt from the Press Release: SARS. MERS. COVID-19. Coronaviruses caused all three diseases, and scientists are betting other members of this viral family will cause new outbreaks. But what…
Read More Emergency Use Authorization (EUA) granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups FDA also authorized the use of Moderna’s booster dose following primary vaccination with other authorized or approved COVID-19 vaccines Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering…
Read More
Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show Equivalent Binding as Original Antibody with No Loss of Biologic Activity Study Indicates AUG-3387 Binds to Both Lambda and Mu Variants of SARS-CoV-2 Excerpt from the Press Release: AUSTIN,…
Read More
Positive unanimous vote for mRNA-1273 booster at the 50 µg dose level for individuals aged 65 and older as well as individuals aged 18 through 64 at high risk of contracting COVID-19 at least 6 months after completion of the primary series Company estimates that booster at the 50 µg dose level could result in…
Read More
Committee Advises Continuation of Trial Without Modification Excerpt from the Press Release: BOSTON, Oct. 13, 2021 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) reviewed safety data from 36 patients treated in the Phase…
Read More